The influence of GLP-1 on glucose-stimulated insulin secretion: Effects on β-cell sensitivity in type 2 and nondiabetic subjects

Diabetes

Volumn 52, Issue 2, 2003, Pages 380-386

  Kjems, Lise L ^a   Holst, Jens J ^b   Vølund, Aage ^c   Madsbad, Sten ^a,d  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c NOVO NORDISK A S   (Denmark)

^d HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; FEMALE; GENE EXPRESSION; HORMONE ACTION; HUMAN; INSULIN LIKE ACTIVITY; INSULIN RELEASE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; SIDE EFFECT;

AREA UNDER CURVE; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE CLAMP TECHNIQUE; HUMANS; INFUSIONS, INTRAVENOUS; INSULIN; ISLETS OF LANGERHANS; KINETICS; MALE; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; REFERENCE VALUES;

EID: 0037312821     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.52.2.380     Document Type: Article

References (32)

1. Ørskov C: Glucagon-like peptide-1, a new hormone on the entero-insular axis. Diabetologia 35:701-711, 1992
2. Holst JJ, Ørskov C: Glucagon and other proglucagon derived peptides. In Gut Peptides: Biochemistry and Physiology. Walsh JH, Dockray GJ, Eds. New York, Raven Press, 1993, p. 305-340
3. Flint A, Raben A, Astrup A, Holst JJ: Glucagon-like peptide 1 promotes satiety and supresses energy intake in humans. J Clin Invest 101:515-520, 1998
4. Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W: Additive insulinotropic effects of exogenous synthetic human gastic inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 76:912-917, 1993
5. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W: Preserved incretin activity of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes. J Clin Invest 91:301-307, 1993
6. Nauck MA, Kleine N, Orskov C, Willms B, Creutzfeldt W: Normalization of fasting hyperglycemia by exogenous GLP-1 (7-36 amide) in type 2-diabetic patients. Diabetologia 36:741-744, 1993
7. Larsson H, Holst JJ, Ahren B: Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiol Scand 160:413-422, 1997
8. Gutniak MK, Orskov C, Holst JJ, Ahren B, Efendic S: Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326:1316-1322, 1992
9. Ritzel R, Orskov C, Holst JJ, Nauck MA: Pharmocokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36] amide after subcutanous injection in healthy volunteers: dose-response-relationships. Diabetologia 38:720-725, 1995
10. Creutfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA: Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I (7-36) amide in type I diabetic patients. Diabetes Care 19:580-586, 1996
11. Ahren B, Larsson H, Holst JJ: Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin dependent diabetes mellitus. J Clin Endocrinol Metab 82:473-478, 1997
12. Rachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, Turner RC: Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1(7-36) amide in patients with NIDDM. Diabetes 45:1524-1530, 1996
13. Byrne MM, Sturis J, Clement K, Vionnet N, Puwyo ME, Smith MJ, Bell GI, Halter JB, Polonsky KS: Insulin secretory abnormalities in subjects with hyperglycemia due to glucokinase mutations. J Clin Invest 93:1120-1130, 1994
14. Byrne MM, Sturis J, Polonsky KS: Insulin secretion and clearance during graded glucose infusion. Am J Physiol 268:E21-E27, 1995
15. Hovorka R, Soons PA, Young MA: ISEC: a program to calculate insulin secretion. Comput Methods Programs Biomed 50:253-264, 1996
16. Hovorka R, Koukou E, Southernden D, Powrie JK, Young MA: Measuring prehepatic insulin secretion using a population model of C-peptide kinetics: accuracy and required sampling schedule. Diabetologia 41:548-554, 1998
17. Krarup T, Nurnberg B, Mikkelsen K, Astrup A, Madsbad S, Henriksen J, Holst JJ: How arterialized is blood sampled from a heated superficial vein (Abstract)? Diabetes 39 (Suppl 1.):88A, 1990
18. Andersen L, Dinesen B, Jorgensen PN, Poulsen F, Røder ME: Enzyme immunoassay of intact insulin in serum and plasma. Clin Chem 39:578-582, 1993
19. Ørskov C, Rabenhøj L, Kofod H, Wettergren A, Holst JJ: Tissue and and plasma concentrations of amidated and glycine-extended glucagon-like peptide-1 in humans. Diabetes 43:535-539, 1994
20. Van Cauter E, Mestrez F, Sturis J, Polonsky KS: Estimation of insulin secretion rates from C-peptide levels: comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 41:368-377, 1992
21. Daniel WW. Biostatistics: A Foundation for Analysis in the Health Sciences. New York, J Wiley, 1983
22. Ørskov C, Wettergren A, Holst JJ: Secretion of the incretin hormones glucagon-like peptide-1 and the gastric inhibitory polypeptides correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol 31665-670, 1996
23. Vilsbøll T, Toft-Nielsen MB, Krarup T, Madsbad S, Dinesen B, Holst JJ: Evaluation of β-cell secretory capacity using glucagon-like peptide 1. Diabetes Care 23:807-812, 2000
24. Larsen J, Damsbo P: Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care 24:1416-1421, 2001
25. Holz IV GG, Kuhtreiber WM, Habener JF: Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like-peptide-1 (7-37). Nature 361:362-365, 1993
26. Brandt A, Katschinski M, Arnold R, Polonsky KS, Göke B, Byrne MM: GLP-1-induced alterations in the glucose-stimulated insulin secretory dose-response curve. Am J Physiol 281:E242-E247, 2001
27. Kløppel G, Løhr M, Habich K, Oberholzer M, Heitz PU: Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv Synth Pathol Res 4:110-125, 1985
28. Robertsen RP: Type II diabetes, glucose "non-sense," and islet desensitization (Review Article). Diabetes 38:1501-1505, 1989
29. Polonsky KS: The B-cell in diabetes: from molecular genetics to clinical research. Diabetes 44:705-717, 1995
30. Porte D Jr: Banting lecture 1990: β-cells in type 2 diabetes mellitus (Review Article). Diabetes 40:166-180, 1991
31. Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte D Jr: Diminished B cell capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Invest 74:1318-1328, 1984
32. Byrne MM, Sturis J, Sobel RJ, Polonsky KS: Elevated plasma glucose 2h postchallenge predicts defects in β-cell function. Am J Physiol 33:E572-E579, 1996